Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (701-710 of 1,058) with videos related to

Pageof 106
Sort By:
Oncotarget|January 18, 2015
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemiaKati Kämpjärvi, Tiina M Järvinen, Tuomas Heikkinen, et al.
Molecular Pharmaceutics|October 27, 2009
Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemiaYan Jin, Shujun Liu, Bo Yu, et al.
Experimental Hematology|May 5, 2015
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivoRajeswaran Mani, Chi-Ling Chiang, Frank W Frissora, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Investigational New Drugs|May 19, 2019
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLJae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, et al.
Haematologica|September 30, 2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patientsJennifer R Brown, John C Byrd, Paolo Ghia, et al.
The New England Journal of Medicine|August 27, 2004
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemiaLaura Z Rassenti, Lang Huynh, Tracy L Toy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapyJonathan P Butchar, Payal Mehta, Steven E Justiniano, et al.
Leukemia|January 24, 2014
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerD M Stephens, A S Ruppert, J A Jones, et al.
Leukemia Research|July 23, 2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemiaDeborah M Stephens, Amy S Ruppert, Kami Maddocks, et al.
Pageof 106

Showing results (701-710 of 1,058) with videos related to

Sort By:
Pageof 106
Oncotarget|January 18, 2015
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemiaKati Kämpjärvi, Tiina M Järvinen, Tuomas Heikkinen, et al.
Molecular Pharmaceutics|October 27, 2009
Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemiaYan Jin, Shujun Liu, Bo Yu, et al.
Experimental Hematology|May 5, 2015
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivoRajeswaran Mani, Chi-Ling Chiang, Frank W Frissora, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
Investigational New Drugs|May 19, 2019
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLJae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, et al.
Haematologica|September 30, 2021
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patientsJennifer R Brown, John C Byrd, Paolo Ghia, et al.
The New England Journal of Medicine|August 27, 2004
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemiaLaura Z Rassenti, Lang Huynh, Tracy L Toy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapyJonathan P Butchar, Payal Mehta, Steven E Justiniano, et al.
Leukemia|January 24, 2014
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerD M Stephens, A S Ruppert, J A Jones, et al.
Leukemia Research|July 23, 2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemiaDeborah M Stephens, Amy S Ruppert, Kami Maddocks, et al.
Pageof 106